Table 1 List of studied P. aeruginosa isolates with antibiotic susceptibility profiles, antibiotics received by patients, genomic variations found between the earliest isolate and late isolates of each patient, and clinical evolution.

From: Rapid genetic and phenotypic changes in Pseudomonas aeruginosa clinical strains during ventilator-associated pneumonia

Isolate	Clinical specimen	Days of mechanical ventilation	Sequence Type	MICs (mg/L)^a						Antibiotic treatment (initiation day)^a	Genomic variation^b	Coding region change	Amino acid change^c	Clinical evolution
Isolate	Clinical specimen	Days of mechanical ventilation	Sequence Type	TIC	TCC	PIP	CAZ	IPM	CIP	Antibiotic treatment (initiation day)^a	Genomic variation^b	Coding region change	Amino acid change^c	Clinical evolution
*Patient 1* ( *strain PA-VAP-1* )
1A	BAL	3 days	1027	16	16	≤4	2	2	≤0.25	CAZ (day 6)	—			death in intensive care unit
1B	BAL	14 days	1027	16	16	≤4	≤1	2	≤0.25		—
1C	BAL	14 days	1027	>64	>64	>64	32	2	≤0.25	IPM/AN (day 17)	SNP	ampD: 358 G > T	AmpD: Glu120*
										IPM/AN (day 17)	SNP	gacA: 601 T > G	GacA: Ser201Ala
*Patient 2* ( *strain PA-VAP-2* )
2A	BAL	4 days	2960	32	32	8	4	0.5	≤0.25	CAZ/CS (day 5)	—			death in intensive care unit
2B	BAL	27 days	2960	64	32	16	4	≥16	≤0.25		INS	oprD: 672_673insC	OprD: Tyr225fs
											SNP	groEL: 560 C > T	GroEL: Pro187Leu
2C	BAL	27 days	2960	32	32	16	4	0.5	≤0.25	FEP/CS (day 30)	SNP	groEL: 560 C > T	GroEL: Pro187Leu
											SNP	pilM: 808 C > T	PilM: Gln270*
											INS	pilE: 208_209insTCGG	PilE: Thr70fs
*Patient 3* ( *strain PA-VAP-3* )
3A	BAL	1 day	253	32	32	16	4	1	2	IPM/TN (day 1)	—			discharge from intensive care unit
3B	BAL	11 days	253	32	16	8	4	1	2	IPM (day 11); CAZ/CS (day 13)	DEL	lasR: 138_148delCTACGAGAACG	LasR: Tyr47fs
										IPM (day 11); CAZ/CS (day 13)	INS	algB: 853_854insCCGCGACCAA	AlgB: Trp288fs
3C	BAL	35 days	253	32	32	8	4	≥16	2	FEP (day 37)	DEL	lasR: 138_148delCTACGAGAACG	LasR: Tyr47fs
										FEP (day 37)	INS	algB: 853_854insCCGCGACCAA	AlgB: Trp288fs
											DEL	oprD: 16_132del117-bp	OprD: loss of 39 AA
											SNP	mpl: 314 T > G	Mpl: Val105Gly
*Patient 4* ( *strain PA-VAP-4* )
4A	BAL	21 days	2042	32	32	16	2	1	≤0.25	FEP/LVX (day 22)	—			discharge from intensive care unit
4B	BAL	46 days	2042	≥128	≥128	64	8	1	1	IPM (day 46)	SNP	lasR: 676 G >A	LasR: Val226Ile
											DEL	rhlA, rhlB, and rhlR: 175_1 del 2186-bp	loss of RhlR & RhlB RhlA: Phe59fs
											INS	mexR: 80_81insT	MexR: Glu27fs
4C	blood culture	48 days	2042	32	16	8	2	1	≤0.25		—

^aAN, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CS, colistin; FEP, cefepime; IPM, imipenem; LVX, levofloxacin; PIP, piperacillin; TCC, ticarcillin-clavulanate; TIC, ticarcillin; TN, tobramycin.
^bDEL, deletion; INS, insertion; SNP, Single Nucleotide Polymorphism.
^c,*STOP codon; AA, amino acids; fs, frameshift mutation.

Back to article page

Table 1 List of studied P. aeruginosa isolates with antibiotic susceptibility profiles, antibiotics received by patients, genomic variations found between the earliest isolate and late isolates of each patient, and clinical evolution.

Search

Quick links